New mRNA vaccine aims to shield toddlers from two winter viruses
NCT ID NCT05743881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing two mRNA vaccines in children aged 5 months to under 24 months. One vaccine targets RSV alone, and the other targets both RSV and hMPV. The main goals are to check safety and see how well the vaccines trigger an immune response. About 186 children will take part, receiving either a vaccine or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA vaccines (mRNA-1345 and mRNA-1365)
What this could lead to
If successful, this could lead to a single vaccine that protects young children against two common respiratory viruses, RSV and hMPV.
What could go wrong
This is an early Phase 1 trial with only 186 participants, so safety and effectiveness are not yet proven. The vaccines may cause side effects or fail to provide strong protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CEVAXIN 24 de Diciembre
Panama City, Panama
-
CEVAXIN Avenida Mexico
Panama City, 0801, Panama
-
CEVAXIN Chorrera
La Chorrera, Panamá Oeste Province, Panama
-
CEVAXIN David
David, Chiriquí Province, 0401, Panama
-
CyFair
Houston, Texas, 77065, United States
-
DM Clinical Research- River Forest
Melrose Park, Illinois, 60160, United States
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27703, United States
-
Matrix Clinical Research
Los Angeles, California, 90057, United States
-
MedPharmics - Platinum - PPDS
Lafayette, Louisiana, 70508, United States
-
Meridian Clinical Research
Washington D.C., District of Columbia, 20016, United States
-
Norfolk and Norwich University Hospitals
Norwich, NR4 7UY, United Kingdom
-
Palmetto Pediatrics, PA
North Charleston, South Carolina, 29406-9170, United States
-
Pediatric Associates
Houston, Texas, 77087, United States
-
Pediatric Center
Richmond, Texas, 77469, United States
-
Vanderbilt Vaccine Research Program
Nashville, Tennessee, 37232, United States
-
Velocity Clinical Research - Providence
Providence, Rhode Island, 02886, United States
-
Village Pediatrics
Plano, Texas, 75024, United States